<DOC>
	<DOCNO>NCT00989664</DOCNO>
	<brief_summary>The result Phase 1/2 ( RIT-I-000 ) Phase 2 ( RIT-II-001 ) study Tositumomab Iodine I 131 Tositumomab ( TST/I-131 TST ) demonstrate TST/ I-131 TST produce high response rate patient chemotherapy-relapsed/refractory , low-grade transform low-grade Non-Hodgkin 's Lymphoma ( NHL ) . On basis result study design compare efficacy TST/ I-131 TST last qualifying chemotherapy regimen patient chemotherapy-refractory , low-grade transform low-grade NHL .</brief_summary>
	<brief_title>Pivotal Study Iodine I 131 Tositumomab Chemotherapy-refractory Low-grade Transformed Low-grade B-cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Iodine-131 anti-B1 antibody</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<mesh_term>Cadexomer iodine</mesh_term>
	<criteria>Male female subject â‰¥18 year age histologically confirm initial diagnosis , previously treat ( least 2 prior chemotherapy regimen ) , lowgrade NHL lowgrade lymphoma transform intermediate highgrade histology . Subjects average 25 % intratrabecular marrow space involve lymphoma bone marrow biopsy specimen assess microscopically within 42 day study entry . Bilateral posterior iliac crest core biopsy require percentage intratrebecular space involve exceed 10 % unilateral biopsy . The mean bilateral biopsy must 25 % . Cytotoxic chemotherapy , radiation therapy , immunosuppressant , cytokine treatment within 4 week prior study entry persistent clinical evidence toxicity . Prior stem cell transplant . Active obstructive hydronephrosis . Evidence active infection require intravenous ( IV ) antibiotic time study entry . New York Heart Association Class III IV heart disease serious illness would preclude evaluation . Prior malignancy lymphoma , except adequately treated skin cancer , situ cervical cancer , cancer subject diseasefree 5 year . Known HIV infection . Known brain leptomeningeal metastasis . Subjects pregnant nursing . Previous allergic reaction iodine . This include reaction intravenous iodinecontaining contrast material . Prior exposure monoclonal polyclonal antibody nonhuman specie either diagnostic therapeutic purpose , include engineer chimeric humanize antibody . Prior radioimmunotherapy . Progressive disease within 1 year irradiation arise field previously irradiate &gt; 3500 cGy . Current use either approve nonapproved ( another protocol ) anticancer drug biologics De novo intermediate highgrade lymphoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>non-Hodgkin 's Lymphoma</keyword>
	<keyword>radioimmunotherapy</keyword>
	<keyword>NHL</keyword>
	<keyword>Bexxar</keyword>
	<keyword>lymphoma</keyword>
	<keyword>Tositumomab</keyword>
</DOC>